Haleon HLN · NYSE
$10.12 +1.81% (+$0.18)
Summary
62 / 100 · Bulios Score
What speaks for it
- Out of every 100 GBP of revenue, 15 GBP is left as net profit.
- Earnings per share grew by 14% a year over the last 3 years.
What to watch
- The share price is above the Bulios Fair Price.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 20.2 GBP for 1 GBP of yearly profit. Over the last five years it was 25.6 GBP on average.
Valuation in detailIs it growing?
SlowlyRevenue (GBP)
Diluted EPS (GBP)
- Analyst estimate
Revenue grew by 1.7% a year over 5 years. Over the last 3 years it fell by 0.2% a year. For the next fiscal year analysts expect revenue to grow by 5.4%. Earnings per share grew by 14% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.99%
- Paid out of profit
- 40%
- Raised in a row
- 2 years
You receive $0.20 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 3
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $10.2 is 0.8% above today's price. 75% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Respiratory Health 65%
- Digestive Health 35%
By region
- Rest of World 56%
- UNITED STATES 35%
- CHINA 8.6%
Respiratory Health brings in 65% of revenue.
Segments in detail